Advertisement

Hémopathies malignes

Chapter
  • 752 Downloads

Résumé

Déf.: Hémopathie maligne de la lignée lymphoïde avec transformation d’un précurseur lymphoblastique, arrêt de la différentiation et expansion clonale. Elle est caractérisée par la suppression de l’hématopoïèse normale, l’infiltration des organes extramédullaires et la libération de cellules leucémiques dans le sang périphérique.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Réf.

  1. 1.
    Aplenc R, Lange B. Pharmacogenetic determinants of outcome in acute lymphoblastic leukemia. Br J Hematol 2004;125:421–434Google Scholar
  2. 2.
    Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol 2005;23:6306–6315PubMedGoogle Scholar
  3. 3.
    Castor A, Nilsson L, Astrand-Grundstroem I et al. Distinct patterns of stem cell involvement in acute lymphoblastic leukemia. Nat Med 2005; 11:630–637PubMedGoogle Scholar
  4. 4.
    Hallbook H, Hagglund H, Stockelberg D et al. Autologous and allogeneic stem cell transplantation in adult ALL. Bone Marrow Transpl 2005;35:1141–1148Google Scholar
  5. 5.
    Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Eng J Med 2006;354:166–178Google Scholar
  6. 6.
    Ravandi F. Role of cytokines in the treatment of acute leukemias. Leukemia 2006;20:563–571PubMedGoogle Scholar
  7. 7.
    Rowe JM, Goldstone AH. How I treat acute lymphocytic leukemia in adults. Blood 2007;110:2268–2275PubMedGoogle Scholar
  8. 8.
    Szczepanski T. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia. Leukemia 2007;21:622–626PubMedGoogle Scholar

Réf.

  1. 1.
    Bullinger L, Valk PJM. Gene-expression profiling in acute myeloid leukemia. J Clin Oncol 2005;23:6296–6305PubMedGoogle Scholar
  2. 2.
    Craddock C, Tauro S, Moss P et al. Biology and management of relapsed acute myeloid leukemia. Br J Hematol 2005;129:18–34Google Scholar
  3. 3.
    Drobyski WR. The role of allogeneic transplantation in high-risk acute myelogenous leukemia. Leukemia 2004;18:1565–1568PubMedGoogle Scholar
  4. 4.
    Estey H, Dönner H. Acute myeloid leukemia. Lancet 2006;368:1894–1907.PubMedGoogle Scholar
  5. 5.
    Fey MF, ESMO Guidelines Task Force. Acute myeloblastic leukemia in adult patients: ESMO Clinical Recommendations for diagnosis, treatment and follow up. Ann Oncol 2007;18(suppl2):ii47–89PubMedGoogle Scholar
  6. 6.
    Milligan DW, Grimwade D, Cullis JO et al. British Committee for Standards in Haematology. Guidelines on the management of acute myeloid leukemia in adults. Br J Haematol 2006;135:450–474PubMedGoogle Scholar
  7. 7.
    Sekeres MA, Stone RM. The challenge of acute myeloid leukemia in older patients. Curr Opin Oncol 2002;14:24–30PubMedGoogle Scholar
  8. 8.
    Tallmann MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005;106:1154–1163Google Scholar
  9. 9.
    Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292–2302PubMedGoogle Scholar

Réf.

  1. 1.
    Aul C, Giagounidis A, Germing U et al. A. Evaluating the prognosis of patients with myelodysplastic syndromes. Ann Hematol 2002; 81:485–497PubMedGoogle Scholar
  2. 2.
    Bowen D, Culligan D, Jowitt S et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Hematol 2003;120:187–200Google Scholar
  3. 3.
    Corey SJ, Minden MD, Barber DL et al. MDS: the complexity of stem-cell diseases. Nat Rev Cancer 2007;7:118–129PubMedGoogle Scholar
  4. 4.
    Golshayan AR, Jin T, Maciejewski J et al. Efficacy of growth factors compared to other therapies for low-risk MDS. Br J Haematol 2007,137:125–132PubMedGoogle Scholar
  5. 5.
    Howe RB, Porwit-MacDonald A, Wanat R et al. The WHO classification of MDS does make a difference. Blood 2004;103:3265–3270PubMedGoogle Scholar
  6. 6.
    Luger S, Sacks N. Bone marrow transplantation for myelodysplastic syndrome: who? when? and which? Bone Marrow Transpl 2002;30:199–206Google Scholar
  7. 7.
    Malcovati L, Germing U, Kuendgen A et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in MDS. J Clin Oncol 2007;25:3503–3510PubMedGoogle Scholar
  8. 8.
    Olney HJ, LeBeau MM. Evaluation of recurring cytogenetic abnormalities in the treatment of MDS. Leukemia Res 2007;31:427–434Google Scholar
  9. 9.
    Valent P, Horny HP, Bennet JM et al. Definitions and standards in the diagnosis and treatment of MDS: Consensus statements and report from a working conference. Leukemia Res 2007;31:727–736Google Scholar

Réf.

  1. 1.
    Campell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006;355:2452–2466Google Scholar
  2. 2.
    James C, Ugo V, LeCouedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature 2005;434:1144–1148PubMedGoogle Scholar
  3. 3.
    Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood 2005;105:4187–4190PubMedGoogle Scholar
  4. 4.
    Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779–1790PubMedGoogle Scholar
  5. 5.
    Michiels JJ, De Raeve H, Hebeda K et al. WHO bone marrow features and European clinical, molecular and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders. Leukemia Res 2007;31:1031–1038Google Scholar
  6. 6.
    Spivak JL, Barosi G, Tognoni G et al. Chronic myeloproliferative disorders. Hematology (ASH Educ Program) 2003:200–224Google Scholar

Réf.

  1. 1.
    Baccarani M, Sglio G, Goldman J et al. Evolving concepts in the management of CML: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006;108:1809–1820PubMedGoogle Scholar
  2. 2.
    Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004;103:4010–4022PubMedGoogle Scholar
  3. 3.
    Cortes C, Kantarjian HM. New targeted approaches in chronic myeloid leukemia. J Clin Oncol 2005;23:6316–6324PubMedGoogle Scholar
  4. 4.
    Goldman J. How I treat CML in the imatinib era. Blood 2007;110:2828–2837PubMedGoogle Scholar
  5. 5.
    Hehlmann R, Hochhaus A, Baccarani M et al. Chronic myeloid leukemia. Lancet 2007;370:342–350PubMedGoogle Scholar
  6. 6.
    Melo JV, Barnes DJ. CML as a model of a disease evolution in human cancer. Nat Rev Cancer 2007;7:441–453PubMedGoogle Scholar
  7. 7.
    Schiffer CA. BCR-ABL tyrosine kinase inhibitors for CML. N Engl J Med 2007;357:258–265PubMedGoogle Scholar
  8. 8.
    Simonsson B, ESMO Guidelines Working Group. CML: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(suppl.2)ii61–62Google Scholar
  9. 9.
    Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukemia. Nat Rev Cancer 2005;5:172–183PubMedGoogle Scholar

Réf.

  1. 1.
    Elliott MA, Tefferi A. Thrombosis and hemorrhage in polycythemia vera and essential thrombocythemia. Br J Hematol 2004; 128:275–290Google Scholar
  2. 2.
    Finazzi G, Caruso V, Marchioli R et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005;105:2664–2670PubMedGoogle Scholar
  3. 3.
    James C, Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature 2005;434:1144–1148PubMedGoogle Scholar
  4. 4.
    Landolfi R, Marchioli R, Kutti J et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114–124PubMedGoogle Scholar
  5. 5.
    Levine L, Pardanani A, Tefferi A et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7:673–683.PubMedGoogle Scholar
  6. 6.
    McMullin MF, Bareford D, Campbell P et al. Guidelines for the diagnosis, investigation and management of polycythemia/erythrocytosis. Br J Hematol 2005;130:174–195Google Scholar
  7. 7.
    Schrader Al. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 2006;107:4214–4222.Google Scholar
  8. 8.
    Tefferi A, Thiele J, Orazi A et al. Proposals and rationale for revision of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092–1097.PubMedGoogle Scholar

Réf.

  1. 1.
    Campbell PJ, Green AR. Management of polycythemia vera and essential thrombocythemia. ASH Educational Program Book 2005:201–208Google Scholar
  2. 2.
    Chim CS, Kwong YL, Lie AK et al. Long-term outcome of 231 patients with essential thrombocythemia. Arch Intern Med 2005;165:2651–2658PubMedGoogle Scholar
  3. 3.
    Finazzi G, Harrison CN. Essential thrombocythemia. Semin Hematol 2005;42:230–238PubMedGoogle Scholar
  4. 4.
    Harrison CN. Essential thrombocythaemia: challenges and evidence-based management. Br J Haematol 2005;130:153–165PubMedGoogle Scholar
  5. 5.
    Harrison CN, Campbell PJ, Buck G et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33–45PubMedGoogle Scholar
  6. 6.
    Schafer AI. Thrombocytosis. N Engl J Med 2004;350:1211–1219PubMedGoogle Scholar
  7. 7.
    Steurer M, Gastl G, Jedrzejczak WW et al. Anagrelide for thrombocytosis in myeloproliferative disorders. Cancer 2004;101:2239–2246PubMedGoogle Scholar
  8. 8.
    Tefferi A, Thiele J, Orazi A et al. Proposals and rationale for revision of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092–1097PubMedGoogle Scholar

Réf.

  1. 1.
    Arana-Yi C, Quintas-Cardama A, Giles F et al. Advances in the therapy of chronic idiopathic myelofibrsis. Oncologist 2006;11:929–943PubMedGoogle Scholar
  2. 2.
    Barosi G, Bergamaschi G, Marchetti M et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007;110:4030–4036PubMedGoogle Scholar
  3. 3.
    Cervantes F. Modern management of myelofibrosis. Br J Haematol 2005;128:585–592Google Scholar
  4. 4.
    Ciurea SO, Merchant D, Mahmud N et al. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood 2007;110:986–993PubMedGoogle Scholar
  5. 5.
    Henessy BT, Thomas DA, Giles FJ et al. New approaches in the treatment of myelofibrosis. Cancer 2005;103:32–43Google Scholar
  6. 6.
    Papageorgiou SG, Castleton A, Bloor A et al. Allogeneic stem cell transplantation as treatment for myelofibrosis. Bone Marrow Transplant 2006;38:721–727PubMedGoogle Scholar
  7. 7.
    Tefferi A, Thiele J, Orazi A et al. Proposals and rationale for revision of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092–1097PubMedGoogle Scholar

Réf.

  1. 1.
    Bonadonna G, Viviani S, Bonafante V et al. Survival in Hodgkin’s lymphoma. Eur J Cancer 2005;41:998–1006PubMedGoogle Scholar
  2. 2.
    Connors JM. State-of-art therapeutics: Hodgkin’s lymphoma. J Clin Oncol 2005;23:6400–6408PubMedGoogle Scholar
  3. 3.
    Diehl V, Fuchs M. Early, intermediate and advanced Hodgkin’s lymphoma: modern treatment strategies. Ann Oncol 2007;18(Suppl. 9):ix71–79PubMedGoogle Scholar
  4. 4.
    Ferme C, Eghbali H, Meerwaldt JH et al. Chemotherapy plus involved field radiation in early stage Hodgkin’s disease. N Engl J Med 2007;357:1916–1927PubMedGoogle Scholar
  5. 5.
    Jost L, ESMO Guidelines Working Group. Hodgkin’s disease: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl. 2):ii53–54PubMedGoogle Scholar
  6. 6.
    Lavoien JC, Connors JM, Phillips GL et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Blood 2005; 106:1473–1478Google Scholar
  7. 7.
    Peggs KS, Hunter A, Chopra R et al. Clinical evidence of graft-versus-Hodgkin’s lymphoma effect after reduced-intensity allogenic transplantation. Lancet 2005;365:1934–1941PubMedGoogle Scholar
  8. 8.
    Re D, Küppers R, Diehl V. Molecular pathogenesis of Hodgkin’s lymphoma. J Clin Oncol 2005;23:6379–6386PubMedGoogle Scholar
  9. 9.
    Yung L, Linch D. Hodgkin’s lymphoma. Lancet 2003;361:943–951PubMedGoogle Scholar

Réf.

  1. 1.
    Armitage JO. Staging non-Hodgkin lymphoma. CA Cancer J Clin 2005;55:368–376PubMedGoogle Scholar
  2. 2.
    Cheson BD, Pflster B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586PubMedGoogle Scholar
  3. 3.
    Evans LS, Hancock BW. Non-Hodgkin lymphoma. Lancet 2003;362:139–146PubMedGoogle Scholar
  4. 4.
    Fisher SG, Fisher RI. The epidemiology of non-Hodgkin’s lymphoma. Oncogene 2004;23:6524–6534PubMedGoogle Scholar
  5. 5.
    Jaffe ES, Harris NL, Stein H et al. (eds) Pathology and Genetics of Tumors of the Hematopoietic and Lymphoid Tissues. WHO classification of tumors, IARC Press, Lyon, 2001Google Scholar
  6. 7.
    Kwee TC, Kwee RM, Nievelstein RAJ. Imaging in staging of malignant lymphoma. Blood 2008;111:504–516PubMedGoogle Scholar
  7. 8.
    Pals ST, De Gorter DJJ, Spaargaren M. Lymphoma dissemination: the other face of lymphocyte homing. Blood 2007;110:3102–3111.PubMedGoogle Scholar
  8. 9.
    Rizvi MA, Evens, AM, Tallman MS et al. T-cell non-Hodgkin lymphoma. Blood 2006; 107:1255–1264PubMedGoogle Scholar

Réf.

  1. 1.
    Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005; 106:1164–1174PubMedGoogle Scholar
  2. 2.
    Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood 2007;110:29–36PubMedGoogle Scholar
  3. 3.
    Coiffier B, Lepage E, Brière J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242PubMedGoogle Scholar
  4. 4.
    ESMO Guidelines Task Force. Relapsed large B-cell non-Hodgkin’ lymphoma. ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl.2):ii55–56Google Scholar
  5. 5.
    ESMO Guidelines Task Force. Newly diagnosed large B-cell non-Hodgkin’s lymphoma. ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl.2):ii57–58Google Scholar
  6. 6.
    Ferry JA. Burkitt’s lymphoma. Oncologist 2006;11:375–383PubMedGoogle Scholar
  7. 7.
    Milpied N, Deconinck E, Gaillard F et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004;350:1287–1295PubMedGoogle Scholar
  8. 8.
    Pfreundschuh M, Trümper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004;104:626–633PubMedGoogle Scholar
  9. 9.
    Seropian S, Bahceci E, Cooper DL. Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin’s lymphoma. Bone Marrow Transpl 2003;32:763–769Google Scholar

Réf.

  1. 1.
    Abbott BL. Chronic lymphocytic leukemia. Oncologist 2006;11:21–30PubMedGoogle Scholar
  2. 2.
    Auer RL, Gribben J, Cotter FE. Emerging therapy for chronic lymphocytic leukaemia. Brit J Haematol 2007;139:635–644.Google Scholar
  3. 3.
    Catovsky D, Richards S, Matutes E et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia. Lancet 2007;370:230–239PubMedGoogle Scholar
  4. 4.
    Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804–815PubMedGoogle Scholar
  5. 5.
    ESMO Guidelines Working Group. Chronic lymphocytic leukemia: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl. 2):ii49–50Google Scholar
  6. 6.
    Montserrat E, Moreno C, Esteve J et al. How I treat refractory CLL. Blood 2006; 107:1276–1283PubMedGoogle Scholar
  7. 7.
    Linet MS, Schubauer-Berigan MK, Weisenburger DD et al. Chronic lymphocytic leukaemia: an overview of aetiology in light of recent developments in classification and pathogenesis. Brit J Haematol 2007;139:672–686.Google Scholar
  8. 8.
    Wierda WG, Kipps TJ, Keating MJ. Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol 2005;23:6325–6332PubMedGoogle Scholar

Réf.

  1. 1.
    Absi H, Hsi E, Kalaycio M. Prolymphocytic leukemia. Curr Treat Options Oncol 2005;6:197–208PubMedGoogle Scholar
  2. 2.
    Cao TM, Coutre SE. T-cell prolymphocytic leukemia: update and focus on alemtuzumab. Hematology 2003;8:1–6PubMedGoogle Scholar
  3. 3.
    Castagna L, Nozza A, Bertuzzi A et al. Allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning in primary refractory prolymphocytic leukemia. Bone Marrow Transplant 2001;28:1155–1166PubMedGoogle Scholar
  4. 4.
    Dearden CE, Matutes E, Cazin B et al. High remission rate in T-cell prolymphocytic leukemia with CAM-PATH-1H. Blood 2001;98:1721–1726PubMedGoogle Scholar
  5. 5.
    McCune SL, Gockerman JP, Moore JO et al. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leuk Lymphoma 2002;43:1007–1011PubMedGoogle Scholar
  6. 6.
    Montillo M, Tedeschi A, O’Brien S et al. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 2003;97:114–120PubMedGoogle Scholar
  7. 7.
    Shvidel L, Shtalrid M, Bassous L et al. B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course. Leuk Lymphoma 1999;33:169–179PubMedGoogle Scholar
  8. 8.
    Valbuena JR, Herling M, Admirand JH et al. T-cell prolymphocytic leukemia involving extramedullary sites. Am J Clin Pathol 2005;123:456–464PubMedGoogle Scholar

Réf.

  1. 1.
    Else M, Ruchlemer R, Osuji N et al. Long remissions in hairy cell leukemia with purine analogues. Cancer 2005;104:2442–2448PubMedGoogle Scholar
  2. 2.
    Falini B, Tiacci E, Liso A et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexinA1 (ANXA1). Lancet 2004;363:1869–1871PubMedGoogle Scholar
  3. 3.
    Goodman GR, Bethel KJ, Saven A. Hairy cell leukemia: an update. Curr Opin Hematol 2003;10:258–266PubMedGoogle Scholar
  4. 4.
    Jehn U, Bartl R, Dietzfelbinger H et al. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004;18:1476–1481PubMedGoogle Scholar
  5. 5.
    Tiacci E, Liso A, Piris M et al. Evolving concepts in the pathogenensis of hairy-cell leukemia. Nat Rev Cancer 2006; 6:437–448PubMedGoogle Scholar
  6. 6.
    Wanko SO, De Castro C. Hairy cell leukemia. Oncologist 2006;11:780–789PubMedGoogle Scholar

Réf.

  1. 1.
    Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin’s lymphoma: long-term followup of no initial therapy. J Clin Oncol 2005;22:1454–1459Google Scholar
  2. 2.
    Bende RJ, Smit LA, Van Noessel CJM. Molecular pathways in follicular lymphoma. Leukemia 2007;21:18–29.PubMedGoogle Scholar
  3. 3.
    Brown J, Feng Y, Gribben JG. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transpl 2007;12:1057–1065.Google Scholar
  4. 4.
    ESMO Guidelines Working Group. Newly diagnosed follicular lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;18(Suppl.2):ii63–64Google Scholar
  5. 5.
    Hiddemann W, Buske C, Dreyling M et al. Current management of follicular lymphomas. Br J Haematol 2006;136:191–202PubMedGoogle Scholar
  6. 6.
    Kaminski MS, Tuck M, Estes J et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441–449PubMedGoogle Scholar
  7. 7.
    Solal-Celigny P, Roy P, Colombat P et al. Follicular Lymphoma International Prognostic Index. Blood 2004;104:1258–1265PubMedGoogle Scholar
  8. 8.
    Staudt LM. A closer look at follicular lymphoma. N Engl J Med 2007;356;741–742.PubMedGoogle Scholar

Réf.

  1. 1.
    Bertoni F, Zucca E, Cavalli F. Mantle cell lymphoma. Curr Opin Hematol 2004;11:411–418PubMedGoogle Scholar
  2. 2.
    Fernàndez V, Hartmann E, Ott G et al. Pathogenesis of mantle cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 2005;23:6364–6369PubMedGoogle Scholar
  3. 3.
    Hagemeister FB. Mantle cell lymphoma: non-myeloablative vs. dose-intensive therapy. Leuk Lymphoma 2003;44(suppl 3):S69–75PubMedGoogle Scholar
  4. 4.
    Kiss TL, Mollee P, Lazarus HM et al. Stem cell transplantation for mantle cell lymphoma: if, when and how? Bone Marrow Transplant 2005;36:655–661PubMedGoogle Scholar
  5. 5.
    Lenz G, Dreyling M, Hiddemann W. Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol 2004;83:71–77PubMedGoogle Scholar
  6. 6.
    Leonard JP, Schattner EJ, Coleman M. Biology and management of mantle cell lymphoma. Curr Opin Oncol 2001;13:342–347PubMedGoogle Scholar
  7. 7.
    Witzig TE. Current treatment approaches for mantle cell lymphoma. J Clin Oncol 2005;23:6409–6414PubMedGoogle Scholar
  8. 8.
    Zelenetz AD. Mantle cell lymphoma. Ann Oncol 2006;17(suppl 4):iv12–14PubMedGoogle Scholar

Réf.

  1. 1.
    ESMO Guidelines Working Group. Primary cutaneous lymphomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl.2):ii61–62Google Scholar
  2. 2.
    Foss F. Mycosis fungoides and the Sézary syndrome. Curr Opin Oncol 2004;16:421–428PubMedGoogle Scholar
  3. 3.
    Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med 2004;350:1978–1988PubMedGoogle Scholar
  4. 4.
    Hwang ST, Janik JE, Jaffe ES et al. Mycosis fungoides and Sézary syndrome. Lancet 2008;371:945–957.PubMedGoogle Scholar
  5. 5.
    Olsen E, Vonderheid E, Pimpinelli N et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the ISCL and the cutaneous lymphoma task force of the EORTC. Blood 2007;110:1713–1722PubMedGoogle Scholar
  6. 6.
    Querfeld C, Rosen ST, Guitart J et al. The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy. Curr Opin Hematol 2005;12:273–278PubMedGoogle Scholar
  7. 7.
    Smith BD, Smith GL, Cooper DL et al. The cutaneous B-cell lymphoma prognostic index. J Clin Oncol 2005;23:3390–3395PubMedGoogle Scholar
  8. 8.
    Trautinger F, Knobler R, Willemze R et al. EORTC consensus recommendations for the treatment of mycosis fungoides / Sézary syndrome. Eur J Cancer 2006;42:1014–1030PubMedGoogle Scholar

Réf.

  1. 1.
    Abrey LE, Batchelor TT, Ferreri AJ et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005;23:5034–5043PubMedGoogle Scholar
  2. 2.
    Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol 2006;24:1281–1288PubMedGoogle Scholar
  3. 3.
    Bessell EM, Hoang-Xuan K, Ferreri AJM et al. Primary central nervous system lymphoma — Biological aspects and controversies in management. Eur J Cancer 2007;43:1141–1152.PubMedGoogle Scholar
  4. 4.
    DeAngelis LM, Hormigo A. Treatment of primary central nervous system lymphoma. Semin Oncol 2004;31:684–692PubMedGoogle Scholar
  5. 5.
    Grimm SA, Pulido JS, Jahnke K et al. Primary intraocular lymphoma: an IPCNSLCG Report. Ann Oncol 2007;18:1851–1855.PubMedGoogle Scholar
  6. 6.
    Nguyen PL, Chakravarti A, Finkelstein DM et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 2005;23:1507–1513PubMedGoogle Scholar
  7. 7.
    Omuro AM, DeAngelis LM, Yahalom J et al. Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology 2005;64:69–74PubMedGoogle Scholar
  8. 8.
    Poortmans PMP, Kluin-Nelemans HC, Haaxma-Reiche H et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma. J Clin Oncol 2003;21:4483–4488PubMedGoogle Scholar
  9. 9.
    Illerhaus G, Marks R, Ihorst G et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006;24:3865–3870PubMedGoogle Scholar

Réf.

  1. 1.
    Bertoni F, Zucca E. State-of-the-art therapeutics: marginal-zone lymphoma. J Clin Oncol 2005;23:6415–6420PubMedGoogle Scholar
  2. 2.
    Cohen SM, Petryk M, Varma M et al. Non-Hodgkin’s Lymhoma of Mucosa-Associated Lymphoid Tissue. Oncolist 2006;11:1100–1117Google Scholar
  3. 3.
    ESMO Guidelines Working Group. Gastric marginal zone lymphoma of mucosa-associated lymphoid tissue type: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl.2):ii59–60Google Scholar
  4. 4.
    Farinha P, Gascoyne R. Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncologist 2005;26:6370–6378Google Scholar
  5. 5.
    Ferrucci PF, Zucca E. Primary gastric lymphoma pathogenesis and treatment: what has changes over the past 10 years? Br J Haematol 2006;136:521–538PubMedGoogle Scholar
  6. 6.
    Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004;4:644–653PubMedGoogle Scholar
  7. 7.
    Schmidt WP, Schmitz N, Sonnen R. Conservative management of gastric lymphoma: the treatment option of choice. Leuk Lymphoma 2004;45:1847–1852PubMedGoogle Scholar

Réf.

  1. 1.
    Bensinger W. Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol 2008;26:480–492PubMedGoogle Scholar
  2. 2.
    Bladé J. Monoclonal Gammopathy of undetermined significance. N Engl J Med 2006;355:2765–2770PubMedGoogle Scholar
  3. 3.
    Dimopoulos M, Spencer A, Attal M et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123–2132PubMedGoogle Scholar
  4. 4.
    ESMO Guidelines Working Group. Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl. 2):ii44–46Google Scholar
  5. 5.
    Gonzalez D, vander Burg M, García-Sanz M et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 2007;110:3112–3121PubMedGoogle Scholar
  6. 6.
    Katzel JA, Hari P, Vesole DH. Multiple Myeloma: Charging Toward a Bright Future. CA Cancer J Clin 2007;57:301–318PubMedGoogle Scholar
  7. 7.
    Kyle RA, Rajkumar SV. Multiple myeloma. Blod 2008;111:2962–2972Google Scholar
  8. 8.
    Kumar SK, Rajkumar SV, Dispenzieri A et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–2520PubMedGoogle Scholar
  9. 9.
    Wechalekar AD, Hawkins PN, Gillmore JD. Perspectives in treatment of AL amyloidosis. Br J Haematol 2008;140:365–377PubMedGoogle Scholar

Réf.

  1. 1.
    Chen CI. Treatment for Waldenström’s macroglobulinemia. Ann Oncol 2004;15:550–558PubMedGoogle Scholar
  2. 2.
    Dimopoulos MA, Kyle RA, Anagnostopoulos A et al. Diagnosis and management of Waldenström’s macroglobulinemia. J Clin Oncol 2005;23:1564–1577PubMedGoogle Scholar
  3. 3.
    Fonseca R, Hayman S. Waldenström macroglobulinaemia. Br J Haematol 2007;138:700–720PubMedGoogle Scholar
  4. 4.
    Johnson SA, Birchall J, Luckie C et al. Guidelines on the management of Waldenström macroglobulinemia. Br J Haematol 2006;132:683–697PubMedGoogle Scholar
  5. 5.
    Kyle RA, Treon SP, Alexanian R et al. Prognostic markers and criteria to initiate therapy in Waldenström’s macroglobulinemia. Semin Oncol 2003;30:116–120PubMedGoogle Scholar
  6. 6.
    Treon SP, Gertz MA, Dimopoulos M et al. Update on treatment recommendations from the Third International Workshop on Waldenström’s macroglobulinemia. Blood 2006; 207:3442–3446Google Scholar

Réf.

  1. 1.
    Aricò M. Langerhans cell histiocytosis in adults: more questions than answers? Eur J Cancer 2004;40:1467–1473PubMedGoogle Scholar
  2. 2.
    Gadner H, Grois N, Pötschger U et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood 2008;111:2556–2562PubMedGoogle Scholar
  3. 3.
    Geissmann F, Lepelletier Y, Fraitag S et al. Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood 2001;97:1241–1248PubMedGoogle Scholar
  4. 4.
    Götz G, Fichter J. Langerhans cell histiocytosis in 58 adults. Eur J Med Res 2004;9:510–514PubMedGoogle Scholar
  5. 5.
    Steiner M, Matthes-Martin S, Attarbaschi A et al. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2005;36:215–225PubMedGoogle Scholar
  6. 6.
    Stockschlaeder M, Sucker C. Adult Langerhans cell histiocytosis. Eur J Haematol 2006;76:363–368PubMedGoogle Scholar
  7. 7.
    Vassallo R, Ryu JH, Colby TV et al. Pulmonary Langerhans cell histiocytosis. N Engl J Med 2000;342:1969–1978PubMedGoogle Scholar

Réf.

  1. 1.
    Akin C, Metcalfe DD. Systemic mastocytosis. Annu Rev Med 2004;55:419–432PubMedGoogle Scholar
  2. 2.
    Kirshenbaum AS, Goff JP, Semere T et al. Demonstration that human mast cells arise from a progenitor cell population that is CD34+,c-kit+, and expresses aminopeptidase N (CD13). Blood 1999;94:2333–2342PubMedGoogle Scholar
  3. 3.
    Ma Y, Zeng S, Metcalfe DD et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors. Blood 1002;99:1741 4Google Scholar
  4. 4.
    Metcalfe DD, Akin C. Mastocytosis: molecular mechanisms and clinical disease heterogeneity. Leuk Res 2001;25:577–582PubMedGoogle Scholar
  5. 5.
    Pardanani A, Ketterling RP, Brockman SR et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003;102:3093–3096PubMedGoogle Scholar
  6. 6.
    Tefferi A, Li CY, Butterfield JH et al. Treatment of systemic mast cell disease with cladribine. N Engl J Med 2001;344:307–309PubMedGoogle Scholar
  7. 7.
    Valent P, Akin C, Sperr WR et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 2005;46:35–48PubMedGoogle Scholar
  8. 8.
    Yavuz AS, Lipsky PE, Yavuz S et al. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood 2002;100:661–665PubMedGoogle Scholar

Copyright information

© Springer-Verlag France, Paris 2011

Authors and Affiliations

There are no affiliations available

Personalised recommendations